Prostate cancer: a review of active surveillance
Lars Lund,1,2 Niels Svolgaard,1 Mads Hvid Poulsen1 1Department of Urology, Odense University Hospital, 2Clinical Institute, Southern University of Southern Denmark, Odense, Denmark Abstract: The objective of this paper is to review the current recommendations for active surveillance in prostate ca...
Main Authors: | , , |
---|---|
Format: | Article |
Language: | English |
Published: |
Dove Medical Press
2014-08-01
|
Series: | Research and Reports in Urology |
Online Access: | http://www.dovepress.com/prostate-cancer-a-review-of-active-surveillance-peer-reviewed-article-RRU |
id |
doaj-3eadbf90a4524a82a7d5cf60184d1705 |
---|---|
record_format |
Article |
spelling |
doaj-3eadbf90a4524a82a7d5cf60184d17052020-11-24T23:11:28ZengDove Medical PressResearch and Reports in Urology2253-24472014-08-012014default10711217978Prostate cancer: a review of active surveillanceLund LSvolgaard NPoulsen MH Lars Lund,1,2 Niels Svolgaard,1 Mads Hvid Poulsen1 1Department of Urology, Odense University Hospital, 2Clinical Institute, Southern University of Southern Denmark, Odense, Denmark Abstract: The objective of this paper is to review the current recommendations for active surveillance in prostate cancer from the present prospective studies. Worldwide, there are increasing numbers of men with prostate cancer. It is now accepted as standard care that a number of men with favorable-risk disease can be followed with active surveillance. In 1995, the first prospective studies were initiated to assess the feasibility of active surveillance, in which the decision to intervene was determined by prostate-specific antigen and/or histological progression. The strategy was to provide therapy individualized to the biological behavior of the cancer. Clinical trials assessing active surveillance have usually included patients younger than 70 years of age, although the guidelines have changed over time for Gleason score and prostate-specific antigen, eg, doubling time, thereby changing the indication for active treatment. The present review focuses on patient selection, prospective studies reported in the literature, and future directions. Keywords: active surveillance, prostate cancer, prospective studies, reviewhttp://www.dovepress.com/prostate-cancer-a-review-of-active-surveillance-peer-reviewed-article-RRU |
collection |
DOAJ |
language |
English |
format |
Article |
sources |
DOAJ |
author |
Lund L Svolgaard N Poulsen MH |
spellingShingle |
Lund L Svolgaard N Poulsen MH Prostate cancer: a review of active surveillance Research and Reports in Urology |
author_facet |
Lund L Svolgaard N Poulsen MH |
author_sort |
Lund L |
title |
Prostate cancer: a review of active surveillance |
title_short |
Prostate cancer: a review of active surveillance |
title_full |
Prostate cancer: a review of active surveillance |
title_fullStr |
Prostate cancer: a review of active surveillance |
title_full_unstemmed |
Prostate cancer: a review of active surveillance |
title_sort |
prostate cancer: a review of active surveillance |
publisher |
Dove Medical Press |
series |
Research and Reports in Urology |
issn |
2253-2447 |
publishDate |
2014-08-01 |
description |
Lars Lund,1,2 Niels Svolgaard,1 Mads Hvid Poulsen1 1Department of Urology, Odense University Hospital, 2Clinical Institute, Southern University of Southern Denmark, Odense, Denmark Abstract: The objective of this paper is to review the current recommendations for active surveillance in prostate cancer from the present prospective studies. Worldwide, there are increasing numbers of men with prostate cancer. It is now accepted as standard care that a number of men with favorable-risk disease can be followed with active surveillance. In 1995, the first prospective studies were initiated to assess the feasibility of active surveillance, in which the decision to intervene was determined by prostate-specific antigen and/or histological progression. The strategy was to provide therapy individualized to the biological behavior of the cancer. Clinical trials assessing active surveillance have usually included patients younger than 70 years of age, although the guidelines have changed over time for Gleason score and prostate-specific antigen, eg, doubling time, thereby changing the indication for active treatment. The present review focuses on patient selection, prospective studies reported in the literature, and future directions. Keywords: active surveillance, prostate cancer, prospective studies, review |
url |
http://www.dovepress.com/prostate-cancer-a-review-of-active-surveillance-peer-reviewed-article-RRU |
work_keys_str_mv |
AT lundl prostatecancerareviewofactivesurveillance AT svolgaardn prostatecancerareviewofactivesurveillance AT poulsenmh prostatecancerareviewofactivesurveillance |
_version_ |
1725604294449692672 |